Form 4: Cullinan Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Anne-Marie Martin, a director of Cullinan Therapeutics, acquired stock options for 15,806 shares of common stock on June 26, 2024.
Summary
- Anne-Marie Martin, a director at Cullinan Therapeutics, Inc. (CGEM), filed a Form 4 on June 27, 2024.
- The filing reports a transaction on June 26, 2024, where Ms. Martin acquired stock options for 15,806 shares of Cullinan Therapeutics' common stock.
- The exercise price of the options is $16.50.
- The options vest fully on the earlier of June 26, 2025, or the date of the Issuer's next annual meeting, contingent upon continued service as a director.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Date of the stock option acquisition. |
| 06/26/2025 | First possible vesting date for the stock options. |
| 06/27/2024 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.